Navigation Links
Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
Date:8/22/2007

MENLO PARK, Calif. and HUNTSVILLE, Ala., Aug. 22 /PRNewswire/ -- DNA2.0 Inc. (http://www.DNA20.com), the largest US provider of synthetic genes, and Operon Biotechnologies (http://www.operon.com), a leader in DNA oligonucleotide synthesis, announce the formation of a partnership to utilize their synergistic technologies and product lines.

By combining Operon's oligonucleotide production platform with DNA2.0's gene synthesis process, the companies expect to further increase DNA2.0's market leading speed of synthesis, while providing Operon access to the fastest growing application area for oligonucleotides today. The partnership will allow each company to remain focused on their respective core businesses, while the customer benefits from the expertise of both partners.

Under the partnership, Operon will co-market DNA2.0's gene synthesis services. 'DNA2.0 provides products and a level of customer service that is unparalleled in the gene synthesis industry, we wholeheartedly recommend them to our customers for their synthetic genes.' said Patrick A. Weiss, CEO of Operon. 'We at Operon are proud to be the primary source of the oligos that go into DNA2.0 synthetic genes.'

'Construction of synthetic genes requires oligos of only the highest quality' said Jeremy Minshull, President of DNA2.0. 'Operon's fully automated oligo synthesis process meets our exacting quality requirements, and their speed and responsiveness makes Operon an outstanding partner for DNA2.0 in the gene synthesis marketplace.'

About DNA2.0 Inc.

DNA2.0 is the largest US provider of synthetic genes, serving customers globally in the pharmaceutical and biotechnology industries as well as in academia. The company is also pioneering the application of machine learning to commercial protein engineering through their ProteinGPS(TM) platform. For more information please visit http://www.DNA20.com.

About Operon Biotechnologies

Operon Biotechnologies is a global market leader in high-throughput synthesis, serving scientists in academic research, biotechnology, and pharmaceutical development. Through our production facilities in the US, Germany, and Japan, as well as distributors worldwide, Operon provides a wide range of quality DNA oligonucleotides, Array Ready Oligo Sets (AROS(TM)) and pre-printed microarrays (OpArray(TM)). Since its inception in 1986, Operon has been driven by incomparable customer service and reliable delivery of quality products. Operon employs advanced synthesis technologies and consistently pursues unique innovations to maintain the highest level of excellence in both products and support. For more information please visit http://www.operon.com.


'/>"/>
SOURCE Operon Biotechnologies
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and recently ... have entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. ... for gene editing across all applications. , Under the terms of the agreement, ...
(Date:10/12/2017)... ... ... AMRI, a global contract research, development and manufacturing organization ... quality of life, will now be offering its impurity solutions as a stand-alone ... for all new drug products, including the finalization of ICH M7 earlier this ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., a ... Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas ... practices and how Proscia improves lab economics and realizes an increase in diagnostic ...
Breaking Biology Technology:
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
Breaking Biology News(10 mins):